Recent developments in the supportive therapy of acute myelogenous leukemia.
The prognosis for patients with AML is improving, but mortality due to bleeding and infection remains significant. HLA compatibility has been the cornerstone of matching for prophylactic platelet transfusion; while HLA matched platelets are often of benefit, we have observed that HLA matching does not reliably predict transfusion responses. The platelet migration inhibition assay is, however, consistently predictive. The matching problem may be circumvented by the use of frozen autologous platelets, which circulate and function hemostatically. In the granulocytopenic patient with de novo fever (frequently due to bacterial sepsis), the immediate empiric use of broad spectrum antibiotics is mandatory. If the marrow begins to recover from chemotherapy shortly after the onset of infection, such that the peripheral granulocyte count will approach normal within 10 days, the likelihood of survival from an episode of septicemia after antibiosis now approaches 80%. If the marrow does not recover shortly, however, the likelihood of survival with antibiosis alone is poor. In this setting, survival is improved if patients are given granulocyte transfusions in addition to antibiotics. Patients who receive chemotherapy in a laminar air-flow room (LAFR) experience fewer severe infections than do patients in a conventional ward. However, most patients who are unresponsive to initial chemotherapy remain so in spite of protection from infection. Thus, the available results do not suggest that the LAFR is likely to improve appreciably the rate or duration of remission. Using malignant lymphoma as a model, we have found that cryopreserved autologous marrow infusions can hasten hematopoietic recovery in man after high-dose chemotherapy, and earlier reconstitution may be of clinical benefit to the patient; techniques are at hand that might permit the application of this concept to AML.
D000380:Agranulocytosis / Q000150:complications; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000628:therapy; D001792:Blood Platelets / Q000276:immunology; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D006098:Granulocytes / Q000637:transplantation; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation; D006470:Hemorrhage / Q000150:complications / Q000628:therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000276:immunology / Q000628:therapy*; D009181:Mycoses / Q000628:therapy; D010356:Patient Isolation; D017713:Platelet Transfusion; D018805:Sepsis / Q000628:therapy; D014182:Transplantation, Autologous
D000900:Anti-Bacterial Agents; D006680:HLA Antigens